NCCN Risk | Low* | Intermediate* | High* | V.high/Metastasis* | Total | |||||
---|---|---|---|---|---|---|---|---|---|---|
N | % | N | % | N | % | N | % | N | % | |
RP | 1,164 | 34.7 | 3,097 | 54.1 | 988 | 33.6 | 57 | 10.4 | 5,306 | 42.2 |
RT | 418 | 12.5 | 1,263 | 22.1 | 958 | 32.6 | 153 | 28.0 | 2,792 | 22.2 |
ADT | 18 | 0.5 | 114 | 2.0 | 469 | 15.9 | 219 | 40.1 | 820 | 6.5 |
No active treatment | 1,483 | 44.2 | 723 | 12.6 | 225 | 7.6 | 18 | 3.3 | 2,449 | 19.5 |
Other | 154 | 4.6 | 307 | 5.4 | 194 | 6.6 | 45 | 8.2 | 700 | 5.6 |
Unknown | 115 | 3.4 | 223 | 3.9 | 109 | 3.7 | 54 | 9.9 | 501 | 4.0 |
Total | 3,352 | 100 | 5,727 | 100 | 2,943 | 100 | 546 | 100 | 12,568 | 100 |
Median [IQR] days to treatment | 119 [63–222.5] |  | 80 [48–137] |  | 49 [29–96] |  | 31 [12–71.5] |  | 75 [41–142] |  |